Welcome to Multibagg AI
Log in to access personalized features
Dashboard
Portfolio
Ask Iris
Discovery
Timeline
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Discover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
Investor Presentation
Q4 FY26
Investor Presentation
Q3 FY26
Investor Presentation
Q2 FY26
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q1 FY26
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q4 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q3 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q2 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q1 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Discovery themes featuring this stock
Discovery themes featuring this stockHealthcare Global Enterprises Ltd (HCG) is currently trading at 639.20 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
HealthCare Global Enterprises Limited is India’s largest dedicated oncology platform operating 22–25 comprehensive cancer centres across 19 cities and Kenya, with integrated diagnostics (Triesta), a fertility vertical (Milann) and advanced radiotherapy assets including 38 LINACs and multiple centres of excellence focused on multidisciplinary, tumor-board led cancer care. Operational momentum in Q3FY26 and 9MFY26 was resilient: 9MF revenue was INR 18,931mn (+15% YoY), volumes rose ~13%, ARPP increased modestly while adjusted EBITDA grew 20% to INR 3,458mn and margins improved to 18.3%, even as reported PAT was impacted by higher depreciation, finance cost and a one-time gratuity adjustment. HCG is differentiating through technology and clinical depth: the North Bangalore greenfield will be the first Bengaluru facility with MR-LINAC, and the company has a track record of early adoption (Varian Ethos, Radixact, CyberKnife), positioning HCG to capture higher-complexity, higher-ARPP cases and strengthen referral economics. Balance sheet and capital dynamics show active investment: net debt ex-cash was INR 7,728mn as of 31 Dec 2025, net debt including leases INR 16,337mn, 9MF capex of INR 2,227mn with planned spend across North Bangalore and Whitefield, and management has signalled a rights issue to further strengthen the capital structure for growth. Digital commercial execution is a visible growth enabler: website-derived digital contribution is 67% of digital revenue, campaign-led revenue rose 38% YoY, mobile app contribution scaled materially and aggregator dependence declined, indicating scalable, higher-quality patient acquisition that should support margin expansion as utilization rises.
Over the past 52 weeks, Healthcare Global Enterprises Ltd has traded between a low of ₹511.83 and a high of ₹799.35. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Healthcare Global Enterprises Ltd has a market capitalization of approximately 9,463.52. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Healthcare Global Enterprises Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 687.76 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 9,463.52 Cr, Healthcare Global Enterprises Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Healthcare Global Enterprises Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Healthcare Global Enterprises Ltd is 687.76. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
HCG has outlined a plan to add about 1,000 beds over the next five years, with a mix of brownfield and greenfield expansion.
The text reports a consolidated net profit of ₹2.17 crore for Q4 FY26, down 70.5% year-on-year from ₹7.36 crore in Q4 FY25.
Healthcare Global Enterprises Ltd reported a standalone net loss of Rs -7.90 crore in Q3 FY25-26 (often rounded to about Rs -7 crore in summaries).
HCG is scheduled to announce its audited Q4 and FY26 results on May 20, 2026.
| Symbol | Watchlist | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
447.75 | 14,247 Cr | 106.97 | 7.03 | 0.00 | 6.58 | 9.75 | 4.27 | ||
1320.00 | 13,472 Cr | 48.40 | 8.17 | 0.26 | 16.89 | 16.88 | 10.15 | ||
293.60 | 12,628 Cr | 49.79 | 6.28 | 0.00 | 12.77 | 17.33 | 9.55 | ||
635.90 | 9,464 Cr | 687.76 | 7.10 | 0.00 | 2.90 | 7.81 | 0.58 | ||
1334.85 | 8,763 Cr | 45.17 | 5.68 | 0.07 | 12.56 | 13.77 | 8.15 | ||
840.00 | 8,081 Cr | 45.88 | 4.54 | 0.00 | 9.85 | 11.09 | 7.50 | ||
5748.75 | 6,289 Cr | 25.73 | 4.77 | 0.26 | 18.53 | 20.76 | 11.83 | ||
| Median: 7 Co. | — | 840.00 | 9,464 Cr | 48.40 | 6.28 | 0.00 | 12.56 | 13.77 | 8.15 |
Bearish
2
Neutral
7
Bullish
5
Bearish
8
Neutral
7
Bullish
31
Bearish
6
Neutral
0
Bullish
26
HealthCare Global Enterprises Limited is India’s largest dedicated oncology platform operating 22–25 comprehensive cancer centres across 19 cities and Kenya, with integrated diagnostics (Triesta), a fertility vertical (Milann) and advanced radiotherapy assets including 38 LINACs and multiple centres of excellence focused on multidisciplinary, tumor-board led cancer care.
Operational momentum in Q3FY26 and 9MFY26 was resilient: 9MF revenue was INR 18,931mn (+15% YoY), volumes rose ~13%, ARPP increased modestly while adjusted EBITDA grew 20% to INR 3,458mn and margins improved to 18.3%, even as reported PAT was impacted by higher depreciation, finance cost and a one-time gratuity adjustment.
HCG is differentiating through technology and clinical depth: the North Bangalore greenfield will be the first Bengaluru facility with MR-LINAC, and the company has a track record of early adoption (Varian Ethos, Radixact, CyberKnife), positioning HCG to capture higher-complexity, higher-ARPP cases and strengthen referral economics.
Balance sheet and capital dynamics show active investment: net debt ex-cash was INR 7,728mn as of 31 Dec 2025, net debt including leases INR 16,337mn, 9MF capex of INR 2,227mn with planned spend across North Bangalore and Whitefield, and management has signalled a rights issue to further strengthen the capital structure for growth.
Digital commercial execution is a visible growth enabler: website-derived digital contribution is 67% of digital revenue, campaign-led revenue rose 38% YoY, mobile app contribution scaled materially and aggregator dependence declined, indicating scalable, higher-quality patient acquisition that should support margin expansion as utilization rises.
Healthcare Services
Hospital
9,543 Cr
Low Risk
693.6
59.2
3.5
7.1
799.35
511.83
Sales CAGR
Profit CAGR
ROE
ROCE
